Inogen Inc (INGN) — SEC Filings
Inogen Inc (INGN) — 40 SEC filings. Latest: 8-K (Apr 6, 2026). Includes 22 8-K, 7 SC 13G/A, 6 10-Q.
Overview
Inogen Inc (INGN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Inogen Inc. reported a net loss of $5.294 million for the three months ended September 30, 2025, an improvement from the $5.963 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $15.620 million, significantly better than the $26.131 million l
Sentiment Summary
Across 40 filings, the sentiment breakdown is: 1 bearish, 38 neutral, 1 mixed. The dominant filing sentiment for Inogen Inc is neutral.
Filing Type Overview
Inogen Inc (INGN) has filed 22 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (40)
Risk Profile
Risk Assessment: Of INGN's 28 recent filings, 1 were flagged as high-risk, 15 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $92.390M |
| Net Income | -$5.294M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $106.476M |
| Operating Margin | N/A |
| Total Assets | $307.009M |
| Total Debt | N/A |
Key Executives
- Brent Burns
- Michael T. Flannery
- Kevin R. Smith
- Nabil Shabshab
- Scott Wilkinson
- Paul J. Hamann
- Michael T. Lio
- Matthew C. Kinder
- Dr. Jonathan M. Weisberg
- Ms. Sarah E. Empey
- Michael L. Borchardt
- Paul J. Estey
- Brent L. Burns
- Michael J. Johnson
Industry Context
Inogen operates in the home healthcare and respiratory device market, specifically focusing on portable oxygen concentrators. The industry is characterized by increasing demand due to an aging global population and a higher prevalence of respiratory conditions. Key trends include technological advancements for more portable and efficient devices, and a shift towards home-based care solutions. Competition is present from both established medical device manufacturers and newer entrants.
Top Tags
sec-filing (5) · financials (5) · financial-condition (4) · results-of-operations (4) · executive-compensation (4) · filing (3) · governance (3) · 10-Q (3) · financial-reporting (2) · executive-change (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (9 months) | $15.620M | Decreased from $26.131M in 2024, a 40.3% improvement |
| Total Revenue (3 months) | $92.390M | Increased from $88.834M in 2024, a 4.0% increase |
| Sales Revenue (3 months) | $79.090M | Increased from $74.929M in 2024, a 5.6% increase |
| Net Cash Used in Operating Activities (9 months) | $10.273M | Shifted from $8.932M provided in 2024, indicating increased cash burn |
| Total Assets | $307.009M | Increased from $296.185M at December 31, 2024 |
| Cash and Cash Equivalents | $106.476M | As of September 30, 2025 |
| Shares Outstanding | 27,148,482 | As of September 30, 2025 |
| Total Operating Expense (3 months) | $48.432M | Decreased from $49.136M in 2024 |
| Net Loss | $10.5M | Increased from $5.2M in Q2 2024, indicating worsening profitability. |
| Customer Concentration | 10% | One customer accounted for 10%+ of net sales for H1 2025, posing significant revenue risk. |
| Supplier Concentration | 10% | Vendor One and Vendor Three each accounted for 10%+ of cost of goods sold for H1 2024, indicating supply chain vulnerability. |
| Accumulated Other Comprehensive Income Loss | $1.2M | Increased from $0.9M in Q2 2024, reflecting negative changes in equity. |
| R&D Expenses | $10.1M | Increased from $9.5M in Q2 2024, showing continued investment in product development. |
| Selling & Marketing Expenses | $35.2M | Increased from $33.8M in H1 2024, indicating ongoing market efforts. |
| General & Administrative Expenses | $20.5M | Increased from $19.8M in H1 2024, reflecting higher operational overhead. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Inogen Inc (INGN)?
Inogen Inc has 40 recent SEC filings from Jan 2024 to Apr 2026, including 22 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of INGN filings?
Across 40 filings, the sentiment breakdown is: 1 bearish, 38 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Inogen Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Inogen Inc (INGN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Inogen Inc?
Key financial highlights from Inogen Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for INGN?
The investment thesis for INGN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Inogen Inc?
Key executives identified across Inogen Inc's filings include Brent Burns, Michael T. Flannery, Kevin R. Smith, Nabil Shabshab, Scott Wilkinson and 9 others.
What are the main risk factors for Inogen Inc stock?
Of INGN's 28 assessed filings, 1 were flagged high-risk, 15 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Inogen Inc?
Forward guidance and predictions for Inogen Inc are extracted from SEC filings as they are enriched.